急性髓系白血病bcl-2与bax基因的比值和耐药

摘要

Objective:To investigate Bcl-2 and Bax gene expression in acute myelogenous Leukemia and the relationship between Bcl-2/Bax ratio and drug resistance.Method:Expression of Bcl-2、Bax was detected by immunohistochemical method while drug resistance of AML was detected by cell culture and MTT assay.Results:A high expression of Bcl-2 and a low expression of Bax were detected in AML,respectively,and the ratio between Bcl-2 and Bax was significantly higher than that in normal control (P＜0.01). The ratio in those who are resistant to chemotherapy was significantly higher than that in those sensitive to chemotherapy (P＜0.05).The responsiveness to chemotherapy of those with a high ratio was poorer than thos with a low ratio (P＜0.05).Conclusion:The alteration of Bcl-2 and Bax played certain role in the development of drug resistance in AML,the test of Bcl-2/Bax ratio may have great significance in choice of chemotherapeutic agents and also provide important information for outcome prediction.%目的：了解凋亡抑制基因(Bcl-2)、凋亡诱导基因(Bax)在急性髓系白血病的表达及Bcl-2/Bax比值与耐药关系。方法：用免疫组织化学法检测Bcl-2、Bax抗原表达，细胞培养四氮唑蓝比色法(MTT)药敏试验检测急性髓系白血病(AML)耐药的情况。结果：AML患者Bcl-2高于正常对照组，Bax低于正常对照组，其Bcl-2/Bax比值显著高于正常对照组(P＜0.01)。产生耐药组的病例Bcl-2/Bax高于敏感组(P＜0.05)，Bcl-2/Bax高比值患者化疗反应差(P＜0.05)。结论：Bcl-2、Bax的异常表达在AML形成、发展和产生耐药起一定作用，检测Bcl-2、Bax比值对治疗药物选择、预后的判断有重要意义。